RUNX2 and cancer: We treated P14 CD8+ T cells to form suitable condition with either the Runx2 inhibitor or vehicle, then coculturing exhausted P14 CD8+ T cells with Hepa1‒6 gp33 cancer cells for 30 h (Fig. 6D).